Scientific opinion on the tolerable upper intake level for folate.

Area of Science:

• Nutrition Science
• Food Safety
• Public Health

Background:

• The European Commission requested a revision of the tolerable upper intake level (UL) for folic acid and its related compounds.
• Concerns existed regarding potential adverse health effects from excess folate intake, including neurological issues and cancer risks.

Purpose of the Study:

• To conduct a scientific opinion on the revision of the UL for folic acid and other folate forms.
• To assess the evidence for adverse health effects associated with high folate intake.

Main Methods:

• Systematic literature reviews were performed to evaluate evidence on priority adverse health effects.
• Specific focus was placed on cobalamin-dependent neuropathy, cognitive decline in low cobalamin status, and risks of colorectal and prostate cancer.

Main Results:

• Evidence was insufficient to establish a causal link between folate intake and impaired cognitive function, colorectal, or prostate cancer.
• The progression of neurological symptoms in cobalamin-deficient patients was identified as the critical effect for UL establishment.
• Existing ULs for folic acid were retained across all population groups, with a new UL of 200 µg/day for infants aged 4-11 months.

Conclusions:

• The established ULs for folic acid and related compounds are considered protective for the general European population.
• Excess intake is unlikely except for individuals regularly consuming high-dose folic acid supplements.
• The risk of neurological symptom progression in cobalamin deficiency remains the key consideration for folate ULs.